Liat Hogen1, Harry Brar1, Allan Covens2, Dina Bassiouny3, Marcus Q Bernardini4, Lilian T Gien2, Sarah E Ferguson4, Danielle Vicus5. 1. Division of Gynecologic Oncology, Sunnybrook Health Sciences Center, Toronto, Ontario, Canada; Division of Gynecologic Oncology, Princess Margaret Cancer Center, Toronto, Ontario, Canada; Department of Obstetrics and Gynecology, University of Toronto, Canada. 2. Division of Gynecologic Oncology, Sunnybrook Health Sciences Center, Toronto, Ontario, Canada; Department of Obstetrics and Gynecology, University of Toronto, Canada. 3. Department of Anatomic Pathology, Sunnybrook Health Sciences Center, Toronto, Ontario, Canada. 4. Division of Gynecologic Oncology, Princess Margaret Cancer Center, Toronto, Ontario, Canada; Department of Obstetrics and Gynecology, University of Toronto, Canada. 5. Division of Gynecologic Oncology, Sunnybrook Health Sciences Center, Toronto, Ontario, Canada; Department of Obstetrics and Gynecology, University of Toronto, Canada. Electronic address: danielle.vicus@sunnybrook.ca.
Abstract
Objective To assess the impact of adjuvant chemotherapy on survival in patients with surgical stageI ovarian clear cell carcinoma (OCCC). METHODS: Data collection and analysis of surgical stageI OCCC patients treated at two tertiary cancer centers was performed. Descriptive statistics, univariate and multivariable analyses and Kaplan-Meier survival probability estimates were completed. RESULTS:Sixty stage I OCCC patients who underwentcomprehensive surgical staging were identified. 29 patients receivedadjuvant chemotherapy and 31 did not. Median follow-up was 4.96 (0.4-16.4) years. The 5-year disease specific survival (DSS) was 84.2%: 95% for stage IA and 76% for stage IB+IC (p=0.16). There were 11 disease specific deaths: 7 in the no adjuvant chemotherapygroup (NACG) and 4 in the adjuvant chemotherapy group (ACG). 5-yearDSS was 84.2%: 74% in NACG and 93% in ACG, (p=0.13). Seventeen patients recurred: 11 in NACG and 6 in ACG (p=0.2). None of the 21 patients with stage I known negative cytology recurred. 5-yearPFS was 74%: 58% in NACG and 86% in ACG (p=0.035). On univariate analysis, no-adjuvant chemotherapy and positive cytology were poor prognostic factors for PFS: HR=2.36, p=0.04 and HR=3.1, p=0.027, respectively. After adjusting for positive cytology, no-adjuvant chemotherapy was still found to significantly correlate with a worse PFS (HR=4, p=0.01). CONCLUSION: Our data supports the use of adjuvant chemotherapy for surgical stage I OCCC. As no patients in our cohort with surgical stage I known negative cytology recurred, more research on the benefit of adjuvant chemotherapy in this group is warranted.
RCT Entities:
Objective To assess the impact of adjuvant chemotherapy on survival in patients with surgical stage I ovarian clear cell carcinoma (OCCC). METHODS: Data collection and analysis of surgical stage I OCCC patients treated at two tertiary cancer centers was performed. Descriptive statistics, univariate and multivariable analyses and Kaplan-Meier survival probability estimates were completed. RESULTS: Sixty stage I OCCC patients who underwent comprehensive surgical staging were identified. 29 patients received adjuvant chemotherapy and 31 did not. Median follow-up was 4.96 (0.4-16.4) years. The 5-year disease specific survival (DSS) was 84.2%: 95% for stage IA and 76% for stage IB+IC (p=0.16). There were 11 disease specific deaths: 7 in the no adjuvant chemotherapy group (NACG) and 4 in the adjuvant chemotherapy group (ACG). 5-year DSS was 84.2%: 74% in NACG and 93% in ACG, (p=0.13). Seventeen patients recurred: 11 in NACG and 6 in ACG (p=0.2). None of the 21 patients with stage I known negative cytology recurred. 5-year PFS was 74%: 58% in NACG and 86% in ACG (p=0.035). On univariate analysis, no-adjuvant chemotherapy and positive cytology were poor prognostic factors for PFS: HR=2.36, p=0.04 and HR=3.1, p=0.027, respectively. After adjusting for positive cytology, no-adjuvant chemotherapy was still found to significantly correlate with a worse PFS (HR=4, p=0.01). CONCLUSION: Our data supports the use of adjuvant chemotherapy for surgical stage I OCCC. As no patients in our cohort with surgical stage I known negative cytology recurred, more research on the benefit of adjuvant chemotherapy in this group is warranted.
Authors: Hee Yeon Lee; Ji Hyung Hong; Jae Ho Byun; Hee-Jun Kim; Sun Kyung Baek; Jin Young Kim; Ki Hyang Kim; Jina Yun; Jung A Kim; Kwonoh Park; Hyo Jin Lee; Jung Lim Lee; Young-Woong Won; Il Hwan Kim; Woo Kyun Bae; Kyong Hwa Park; Der-Sheng Sun; Suee Lee; Min-Young Lee; Guk Jin Lee; Sook Hee Hong; Yun Hwa Jung; Ho Jung An Journal: Cancer Res Treat Date: 2019-07-12 Impact factor: 4.679